Table 1:
Baseline characteristics stratified by frailty index tertiles
| Variable | Non-Frail FI Class 1 (N=163) | Intermediate Frailty FI Class 2 (N=221) | High Frailty FI Class 3 (N=495) | P-value |
|---|---|---|---|---|
| Frailty Index | 0.163 [0.0278, 0.209] | 0.270 [0.210, 0.310] | 0.402 [0.310, 0.738] | <0.001 |
| Age, years | 58.0 [48.0, 68.0] | 63.0 [54.0, 72.0] | 64.0 [54.0, 72.0] | 0.001 |
| Female, % | 27.0 | 29.0 | 34.1 | 0.15 |
| White, % | 49.1 | 52.9 | 58.0 | 0.11 |
| BMI, kg/m 2 | 27.6 [24.3, 31.6] | 28.1 [24.7, 33.1] | 29.4 [24.8, 34.9] | 0.01 |
| NYHA Class I-II | 75.3 | 64.5 | 48.7 | <0.001 |
| Ejection Fraction | 20.0 [4.00, 40.0] | 22.5 [6.00, 40.0] | 25.0 [5.00, 40.0] | <0.001 |
| NT-Pro BNP | 2056 [103.0, 21293] | 2326 [49–61750] | 3004 [49–104280] | <0.001 |
| COPD, % | 6.1 | 18.1 | 28.3 | <0.001 |
| Ischemic HF, % | 31.6 | 31.2 | 56.6 | <0.001 |
| Diabetes, % | 24.5 | 41.6 | 43.4 | <0.001 |
| Atrial fib, % | 28.2 | 33.9 | 46.3 | <0.001 |
| PVD, % | 2.5 | 7.2 | 14.5 | <0.001 |
| Sleep Apnea, % | 8.0 | 18.1 | 29.7 | <0.001 |
| Kidney Disease, % | 14.1 | 32.6 | 46.3 | <0.001 |
| eGFR | 70 (55 – 86) | 61 (46 – 74) | 50 (36 – 72) | <0.001 |
| Stroke, % | 1.8 | 7.7 | 14.5 | <0.001 |
| Antidepressant, % | 6.7 | 8.1 | 21.6 | <0.001 |
| Biomarker arm, % | 54.6 | 52.0 | 47.1 | 0.18 |
| ACE or ARB, % | 36.2 | 30.8 | 29.5 | 0.275 |
| Beta blocker, % | 27.0 | 31.2 | 35.2 | 0.136 |
| Aldosterone antagonist, % | 60.1 | 47.1 | 48.1 | 0.02 |
| Double therapy, % | 38.7 | 30.8 | 31.7 | 0.201 |
| Triple therapy, % | 9.8 | 7.7 | 9.3 | 0.724 |
Data were presented as median (25th percentile – 75th percentile) for continuous and number (percentage) for categorical variables.
*
Abbreviation: SD, standard deviation; BMI, basal metabolic rate; NYHA, New York Heart Association; NT-Pro BNP, amino terminal pro-B type natriuretic peptide